Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Targeted Drugs for NSCLC market report explains the definition, types, applications, major countries, and major players of the Targeted Drugs for NSCLC market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Cipla
Boehringer-Ingelheim
Hetero Drugs
Celgene Corporation
Amgen
Biocon
Genvio Pharma Limited
Novartis
AstraZeneca
ImClone Systems (Eli Lilly)
Incepta Pharmaceuticals
OSI Pharmaceuticals
Roche
Teva
Natco Pharma
Pfizer
Mylan
ARIAD Pharmaceuticals (Takeda)
Glenmark Pharmaceuticals
Beacon Pharma Limited
Fujifilm Kyowa Kirin Biologics
BeiGene
Reliance Lifesciences
Drug International Limted
Allergan
By Type:
Target EGFR
Target ALK
Target HER2
Target ROS1
Target BRAF
Target MEK
Target VEGFR2
Target VEGF
Target MET
By End-User:
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Targeted Drugs for NSCLC Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Targeted Drugs for NSCLC Outlook to 2028- Original Forecasts
-
2.2 Targeted Drugs for NSCLC Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Targeted Drugs for NSCLC Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Targeted Drugs for NSCLC Market- Recent Developments
-
6.1 Targeted Drugs for NSCLC Market News and Developments
-
6.2 Targeted Drugs for NSCLC Market Deals Landscape
7 Targeted Drugs for NSCLC Raw Materials and Cost Structure Analysis
-
7.1 Targeted Drugs for NSCLC Key Raw Materials
-
7.2 Targeted Drugs for NSCLC Price Trend of Key Raw Materials
-
7.3 Targeted Drugs for NSCLC Key Suppliers of Raw Materials
-
7.4 Targeted Drugs for NSCLC Market Concentration Rate of Raw Materials
-
7.5 Targeted Drugs for NSCLC Cost Structure Analysis
-
7.5.1 Targeted Drugs for NSCLC Raw Materials Analysis
-
7.5.2 Targeted Drugs for NSCLC Labor Cost Analysis
-
7.5.3 Targeted Drugs for NSCLC Manufacturing Expenses Analysis
8 Global Targeted Drugs for NSCLC Import and Export Analysis (Top 10 Countries)
-
8.1 Global Targeted Drugs for NSCLC Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Targeted Drugs for NSCLC Export by Region (Top 10 Countries) (2017-2028)
9 Global Targeted Drugs for NSCLC Market Outlook by Types and Applications to 2022
-
9.1 Global Targeted Drugs for NSCLC Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Target EGFR Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Target ALK Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Target HER2 Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Target ROS1 Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Target BRAF Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Target MEK Consumption and Growth Rate (2017-2022)
-
9.1.7 Global Target VEGFR2 Consumption and Growth Rate (2017-2022)
-
9.1.8 Global Target VEGF Consumption and Growth Rate (2017-2022)
-
9.1.9 Global Target MET Consumption and Growth Rate (2017-2022)
-
9.2 Global Targeted Drugs for NSCLC Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Squamous Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Adenocarcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Large Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Targeted Drugs for NSCLC Market Analysis and Outlook till 2022
-
10.1 Global Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.2.2 Canada Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.2.3 Mexico Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.3.2 UK Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.3.3 Spain Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.3.4 Belgium Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.3.5 France Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.3.6 Italy Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.3.7 Denmark Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.3.8 Finland Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.3.9 Norway Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.3.10 Sweden Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.3.11 Poland Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.3.12 Russia Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.3.13 Turkey Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.4.2 Japan Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.4.3 India Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.4.4 South Korea Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.4.5 Pakistan Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.4.6 Bangladesh Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.4.7 Indonesia Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.4.8 Thailand Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.4.9 Singapore Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.4.10 Malaysia Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.4.11 Philippines Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.4.12 Vietnam Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.5.2 Colombia Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.5.3 Chile Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.5.4 Argentina Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.5.5 Venezuela Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.5.6 Peru Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.5.7 Puerto Rico Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.5.8 Ecuador Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.6.2 Kuwait Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.6.3 Oman Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.6.4 Qatar Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.6.5 Saudi Arabia Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.6.6 United Arab Emirates Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.7.2 South Africa Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.7.3 Egypt Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.7.4 Algeria Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Targeted Drugs for NSCLC Consumption (2017-2022)
-
10.8.2 New Zealand Targeted Drugs for NSCLC Consumption (2017-2022)
11 Global Targeted Drugs for NSCLC Competitive Analysis
-
11.1 Cipla
-
11.1.1 Cipla Company Details
-
11.1.2 Cipla Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Cipla Targeted Drugs for NSCLC Main Business and Markets Served
-
11.1.4 Cipla Targeted Drugs for NSCLC Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Boehringer-Ingelheim
-
11.2.1 Boehringer-Ingelheim Company Details
-
11.2.2 Boehringer-Ingelheim Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Main Business and Markets Served
-
11.2.4 Boehringer-Ingelheim Targeted Drugs for NSCLC Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Hetero Drugs
-
11.3.1 Hetero Drugs Company Details
-
11.3.2 Hetero Drugs Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Hetero Drugs Targeted Drugs for NSCLC Main Business and Markets Served
-
11.3.4 Hetero Drugs Targeted Drugs for NSCLC Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Celgene Corporation
-
11.4.1 Celgene Corporation Company Details
-
11.4.2 Celgene Corporation Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Celgene Corporation Targeted Drugs for NSCLC Main Business and Markets Served
-
11.4.4 Celgene Corporation Targeted Drugs for NSCLC Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Amgen
-
11.5.1 Amgen Company Details
-
11.5.2 Amgen Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Amgen Targeted Drugs for NSCLC Main Business and Markets Served
-
11.5.4 Amgen Targeted Drugs for NSCLC Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Biocon
-
11.6.1 Biocon Company Details
-
11.6.2 Biocon Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Biocon Targeted Drugs for NSCLC Main Business and Markets Served
-
11.6.4 Biocon Targeted Drugs for NSCLC Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Genvio Pharma Limited
-
11.7.1 Genvio Pharma Limited Company Details
-
11.7.2 Genvio Pharma Limited Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Genvio Pharma Limited Targeted Drugs for NSCLC Main Business and Markets Served
-
11.7.4 Genvio Pharma Limited Targeted Drugs for NSCLC Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Novartis
-
11.8.1 Novartis Company Details
-
11.8.2 Novartis Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Novartis Targeted Drugs for NSCLC Main Business and Markets Served
-
11.8.4 Novartis Targeted Drugs for NSCLC Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 AstraZeneca
-
11.9.1 AstraZeneca Company Details
-
11.9.2 AstraZeneca Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 AstraZeneca Targeted Drugs for NSCLC Main Business and Markets Served
-
11.9.4 AstraZeneca Targeted Drugs for NSCLC Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 ImClone Systems (Eli Lilly)
-
11.10.1 ImClone Systems (Eli Lilly) Company Details
-
11.10.2 ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Main Business and Markets Served
-
11.10.4 ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Incepta Pharmaceuticals
-
11.11.1 Incepta Pharmaceuticals Company Details
-
11.11.2 Incepta Pharmaceuticals Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Main Business and Markets Served
-
11.11.4 Incepta Pharmaceuticals Targeted Drugs for NSCLC Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 OSI Pharmaceuticals
-
11.12.1 OSI Pharmaceuticals Company Details
-
11.12.2 OSI Pharmaceuticals Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Main Business and Markets Served
-
11.12.4 OSI Pharmaceuticals Targeted Drugs for NSCLC Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Roche
-
11.13.1 Roche Company Details
-
11.13.2 Roche Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Roche Targeted Drugs for NSCLC Main Business and Markets Served
-
11.13.4 Roche Targeted Drugs for NSCLC Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Teva
-
11.14.1 Teva Company Details
-
11.14.2 Teva Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Teva Targeted Drugs for NSCLC Main Business and Markets Served
-
11.14.4 Teva Targeted Drugs for NSCLC Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Natco Pharma
-
11.15.1 Natco Pharma Company Details
-
11.15.2 Natco Pharma Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Natco Pharma Targeted Drugs for NSCLC Main Business and Markets Served
-
11.15.4 Natco Pharma Targeted Drugs for NSCLC Product Portfolio
-
11.15.5 Recent Research and Development Strategies
-
11.16 Pfizer
-
11.16.1 Pfizer Company Details
-
11.16.2 Pfizer Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.16.3 Pfizer Targeted Drugs for NSCLC Main Business and Markets Served
-
11.16.4 Pfizer Targeted Drugs for NSCLC Product Portfolio
-
11.16.5 Recent Research and Development Strategies
-
11.17 Mylan
-
11.17.1 Mylan Company Details
-
11.17.2 Mylan Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.17.3 Mylan Targeted Drugs for NSCLC Main Business and Markets Served
-
11.17.4 Mylan Targeted Drugs for NSCLC Product Portfolio
-
11.17.5 Recent Research and Development Strategies
-
11.18 ARIAD Pharmaceuticals (Takeda)
-
11.18.1 ARIAD Pharmaceuticals (Takeda) Company Details
-
11.18.2 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.18.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Main Business and Markets Served
-
11.18.4 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product Portfolio
-
11.18.5 Recent Research and Development Strategies
-
11.19 Glenmark Pharmaceuticals
-
11.19.1 Glenmark Pharmaceuticals Company Details
-
11.19.2 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.19.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Main Business and Markets Served
-
11.19.4 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product Portfolio
-
11.19.5 Recent Research and Development Strategies
-
11.20 Beacon Pharma Limited
-
11.20.1 Beacon Pharma Limited Company Details
-
11.20.2 Beacon Pharma Limited Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.20.3 Beacon Pharma Limited Targeted Drugs for NSCLC Main Business and Markets Served
-
11.20.4 Beacon Pharma Limited Targeted Drugs for NSCLC Product Portfolio
-
11.20.5 Recent Research and Development Strategies
-
11.21 Fujifilm Kyowa Kirin Biologics
-
11.21.1 Fujifilm Kyowa Kirin Biologics Company Details
-
11.21.2 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.21.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Main Business and Markets Served
-
11.21.4 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product Portfolio
-
11.21.5 Recent Research and Development Strategies
-
11.22 BeiGene
-
11.22.1 BeiGene Company Details
-
11.22.2 BeiGene Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.22.3 BeiGene Targeted Drugs for NSCLC Main Business and Markets Served
-
11.22.4 BeiGene Targeted Drugs for NSCLC Product Portfolio
-
11.22.5 Recent Research and Development Strategies
-
11.23 Reliance Lifesciences
-
11.23.1 Reliance Lifesciences Company Details
-
11.23.2 Reliance Lifesciences Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.23.3 Reliance Lifesciences Targeted Drugs for NSCLC Main Business and Markets Served
-
11.23.4 Reliance Lifesciences Targeted Drugs for NSCLC Product Portfolio
-
11.23.5 Recent Research and Development Strategies
-
11.24 Drug International Limted
-
11.24.1 Drug International Limted Company Details
-
11.24.2 Drug International Limted Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.24.3 Drug International Limted Targeted Drugs for NSCLC Main Business and Markets Served
-
11.24.4 Drug International Limted Targeted Drugs for NSCLC Product Portfolio
-
11.24.5 Recent Research and Development Strategies
-
11.25 Allergan
-
11.25.1 Allergan Company Details
-
11.25.2 Allergan Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.25.3 Allergan Targeted Drugs for NSCLC Main Business and Markets Served
-
11.25.4 Allergan Targeted Drugs for NSCLC Product Portfolio
-
11.25.5 Recent Research and Development Strategies
12 Global Targeted Drugs for NSCLC Market Outlook by Types and Applications to 2028
-
12.1 Global Targeted Drugs for NSCLC Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Target EGFR Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Target ALK Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Target HER2 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Target ROS1 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Target BRAF Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global Target MEK Consumption Forecast and Growth Rate (2022-2028)
-
12.1.7 Global Target VEGFR2 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.8 Global Target VEGF Consumption Forecast and Growth Rate (2022-2028)
-
12.1.9 Global Target MET Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Targeted Drugs for NSCLC Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Squamous Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Adenocarcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Large Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Targeted Drugs for NSCLC Market Analysis and Outlook to 2028
-
13.1 Global Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.2.2 Canada Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.2.3 Mexico Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.3.2 UK Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.3.3 Spain Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.3.4 Belgium Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.3.5 France Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.3.6 Italy Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.3.7 Denmark Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.3.8 Finland Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.3.9 Norway Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.3.10 Sweden Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.3.11 Poland Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.3.12 Russia Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.3.13 Turkey Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.4.2 Japan Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.4.3 India Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.4.4 South Korea Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.4.8 Thailand Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.4.9 Singapore Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.4.11 Philippines Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.5.2 Colombia Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.5.3 Chile Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.5.4 Argentina Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.5.6 Peru Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.6.3 Oman Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.6.4 Qatar Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.7.2 South Africa Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.7.3 Egypt Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.7.4 Algeria Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Targeted Drugs for NSCLC Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Targeted Drugs for NSCLC
-
Figure of Targeted Drugs for NSCLC Picture
-
Table Global Targeted Drugs for NSCLC Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Targeted Drugs for NSCLC Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Target EGFR Consumption and Growth Rate (2017-2022)
-
Figure Global Target ALK Consumption and Growth Rate (2017-2022)
-
Figure Global Target HER2 Consumption and Growth Rate (2017-2022)
-
Figure Global Target ROS1 Consumption and Growth Rate (2017-2022)
-
Figure Global Target BRAF Consumption and Growth Rate (2017-2022)
-
Figure Global Target MEK Consumption and Growth Rate (2017-2022)
-
Figure Global Target VEGFR2 Consumption and Growth Rate (2017-2022)
-
Figure Global Target VEGF Consumption and Growth Rate (2017-2022)
-
Figure Global Target MET Consumption and Growth Rate (2017-2022)
-
Figure Global Squamous Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Global Adenocarcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Global Large Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Global Targeted Drugs for NSCLC Consumption by Country (2017-2022)
-
Table North America Targeted Drugs for NSCLC Consumption by Country (2017-2022)
-
Figure United States Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Canada Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Mexico Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Table Europe Targeted Drugs for NSCLC Consumption by Country (2017-2022)
-
Figure Germany Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure UK Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Spain Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Belgium Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure France Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Italy Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Denmark Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Finland Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Norway Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Sweden Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Poland Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Russia Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Turkey Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Table APAC Targeted Drugs for NSCLC Consumption by Country (2017-2022)
-
Figure China Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Japan Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure India Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure South Korea Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Thailand Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Singapore Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Philippines Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Table South America Targeted Drugs for NSCLC Consumption by Country (2017-2022)
-
Figure Brazil Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Colombia Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Chile Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Argentina Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Peru Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Table GCC Targeted Drugs for NSCLC Consumption by Country (2017-2022)
-
Figure Bahrain Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Oman Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Qatar Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Table Africa Targeted Drugs for NSCLC Consumption by Country (2017-2022)
-
Figure Nigeria Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure South Africa Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Egypt Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Algeria Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Table Oceania Targeted Drugs for NSCLC Consumption by Country (2017-2022)
-
Figure Australia Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)
-
Table Cipla Company Details
-
Table Cipla Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cipla Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Cipla Targeted Drugs for NSCLC Product Portfolio
-
Table Boehringer-Ingelheim Company Details
-
Table Boehringer-Ingelheim Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer-Ingelheim Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Boehringer-Ingelheim Targeted Drugs for NSCLC Product Portfolio
-
Table Hetero Drugs Company Details
-
Table Hetero Drugs Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Hetero Drugs Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Hetero Drugs Targeted Drugs for NSCLC Product Portfolio
-
Table Celgene Corporation Company Details
-
Table Celgene Corporation Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celgene Corporation Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Celgene Corporation Targeted Drugs for NSCLC Product Portfolio
-
Table Amgen Company Details
-
Table Amgen Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Amgen Targeted Drugs for NSCLC Product Portfolio
-
Table Biocon Company Details
-
Table Biocon Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biocon Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Biocon Targeted Drugs for NSCLC Product Portfolio
-
Table Genvio Pharma Limited Company Details
-
Table Genvio Pharma Limited Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genvio Pharma Limited Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Genvio Pharma Limited Targeted Drugs for NSCLC Product Portfolio
-
Table Novartis Company Details
-
Table Novartis Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Novartis Targeted Drugs for NSCLC Product Portfolio
-
Table AstraZeneca Company Details
-
Table AstraZeneca Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Targeted Drugs for NSCLC Main Business and Markets Served
-
Table AstraZeneca Targeted Drugs for NSCLC Product Portfolio
-
Table ImClone Systems (Eli Lilly) Company Details
-
Table ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Main Business and Markets Served
-
Table ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Product Portfolio
-
Table Incepta Pharmaceuticals Company Details
-
Table Incepta Pharmaceuticals Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Incepta Pharmaceuticals Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Incepta Pharmaceuticals Targeted Drugs for NSCLC Product Portfolio
-
Table OSI Pharmaceuticals Company Details
-
Table OSI Pharmaceuticals Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table OSI Pharmaceuticals Targeted Drugs for NSCLC Main Business and Markets Served
-
Table OSI Pharmaceuticals Targeted Drugs for NSCLC Product Portfolio
-
Table Roche Company Details
-
Table Roche Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Roche Targeted Drugs for NSCLC Product Portfolio
-
Table Teva Company Details
-
Table Teva Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Teva Targeted Drugs for NSCLC Product Portfolio
-
Table Natco Pharma Company Details
-
Table Natco Pharma Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Natco Pharma Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Natco Pharma Targeted Drugs for NSCLC Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Pfizer Targeted Drugs for NSCLC Product Portfolio
-
Table Mylan Company Details
-
Table Mylan Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Mylan Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Mylan Targeted Drugs for NSCLC Product Portfolio
-
Table ARIAD Pharmaceuticals (Takeda) Company Details
-
Table ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Main Business and Markets Served
-
Table ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product Portfolio
-
Table Glenmark Pharmaceuticals Company Details
-
Table Glenmark Pharmaceuticals Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Glenmark Pharmaceuticals Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product Portfolio
-
Table Beacon Pharma Limited Company Details
-
Table Beacon Pharma Limited Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Beacon Pharma Limited Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Beacon Pharma Limited Targeted Drugs for NSCLC Product Portfolio
-
Table Fujifilm Kyowa Kirin Biologics Company Details
-
Table Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product Portfolio
-
Table BeiGene Company Details
-
Table BeiGene Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table BeiGene Targeted Drugs for NSCLC Main Business and Markets Served
-
Table BeiGene Targeted Drugs for NSCLC Product Portfolio
-
Table Reliance Lifesciences Company Details
-
Table Reliance Lifesciences Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Reliance Lifesciences Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Reliance Lifesciences Targeted Drugs for NSCLC Product Portfolio
-
Table Drug International Limted Company Details
-
Table Drug International Limted Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Drug International Limted Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Drug International Limted Targeted Drugs for NSCLC Product Portfolio
-
Table Allergan Company Details
-
Table Allergan Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Allergan Targeted Drugs for NSCLC Main Business and Markets Served
-
Table Allergan Targeted Drugs for NSCLC Product Portfolio
-
Figure Global Target EGFR Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Target ALK Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Target HER2 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Target ROS1 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Target BRAF Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Target MEK Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Target VEGFR2 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Target VEGF Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Target MET Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Squamous Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Adenocarcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Large Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Targeted Drugs for NSCLC Consumption Forecast by Country (2022-2028)
-
Table North America Targeted Drugs for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure United States Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Targeted Drugs for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Germany Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Targeted Drugs for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure China Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Targeted Drugs for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Brazil Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Targeted Drugs for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Targeted Drugs for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Targeted Drugs for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Australia Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
